Trial Condition(s):


BAY80-6946 open label, phase I study in patients with advanced cancer

Bayer Identifier:

12871 Identifier:


EudraCT Number:

Not Available

EU CT Number:

Not Available

Study Completed

Trial Purpose

The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.

Inclusion Criteria
- Age >/= 18 years.
 - Histological or cytological documentation of non-hematologic, malignant solid tumor, excluding primary brain or spinal tumors, or history of central nervous system metastases
 - At least one measurable lesion or evaluable disease
 - Life expectancy of at least 12 weeks
 - ECOG Performance Status of 0, 1 or 2
 - PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists]. Low-dose aspirin is permitted (</= 100 mg daily).
 - Adequate bone marrow, liver and renal function
 - Ability to understand and  to sign an informed consent form; a signed informed consent must be obtained prior to any study specific procedures
Exclusion Criteria
- History of cardiac disease congestive heart failure (CHF) > NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset angina within 3 months prior to study entry or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or Digoxin are permitted).
 - Current diagnosis of type I or II diabetes mellitus or fasting blood glucose level >125 mg/dL at screening, or HbA1c 7%
 - Active clinically serious infections > Grade 2 (NCI-CTCAE Version 3.0)
 - History of having received allogeneic organ transplant
 - Uncontrolled seizure disorder. Use of cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or phenobarbital) is not allowed throughout the entire study.
 - Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management

Trial Summary

Enrollment Goal
Trial Dates
Could I receive a placebo?
Aliqopa (Copanlisib, BAY80-6946)
Accepts Healthy Volunteers

Where to Participate


Investigative Site

Pittsburgh, United States, 15213


Investigative Site

San Antonio, United States, 78229-3307


Investigative Site

Scottsdale, United States, 85258

Trial Design